Hepagene hepatitis B vaccine containing all HBV surface antigens data

MDV announced results of a U.K. trial demonstrating Hepagene's effectiveness in 925 patients who were not seroprotected after at least 3 doses of Engerix-B, a vaccine produced by SmithKline Beecham (Philadelphia, Penn.). Patients received either a single dose of Hepagene or Engerix-B.

Single doses of Hepagene seroconverted 80 percent and seroprotected 68 percent of patients. In comparison, single doses of Engerix-B seroconverted 69 percent and seroprotected 55 percent. Average blood level response for Engerix-B was 74 IU/1 and for Hepagene was 140 IU/1, demonstrating that Hepagene produced a greater immune response. All differences were statistically significant. ...